{
    "clinical_study": {
        "@rank": "3330", 
        "arm_group": [
            {
                "arm_group_label": "HGT1a", 
                "description": "HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months)."
            }, 
            {
                "arm_group_label": "HGT1b", 
                "description": "HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months)."
            }
        ], 
        "biospec_descr": {
            "textblock": "paraffin embedded blocks of transurethral resection (TUR) samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Non-muscle invasive bladder cancer of High Grade stage T1 (HGT1), has up to 20% risk of\n      progression to invasive disease. Because the depth of substaging seems to identify two\n      separate groups with different progression risk (HighGradeT1a and HighGradeT1b), we design a\n      differential treatment strategy for each group. The main hypothesis is that HighGradeT1a\n      bladder cancer can spare a second endoscopic procedure."
        }, 
        "brief_title": "Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Only cases of initial diagnosis of HighGradeT1 and with a complete transurethral endoscopic\n      resection (TUR) of bladder tumor) can enter this protocol. HighGradeT1a will only receive\n      standard BCG treatment (induction and maintenance). HighGradeT1b will undergo a second\n      transurethral endoscopic resection (TUR) after the induction of Bacillus de Calmette-Guerin\n      (BCG) and then continue mantenaince BCG and standard follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HGT1 bladder cancer at initial diagnosis and after a complete TUR\n\n        Exclusion Criteria:\n\n          -  abscence of muscularis propria in the TUR specimen"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Initial HGT1 bladder cancer patients that have undergone a complete TUR and are willing to\n        enter the protocol."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02113501", 
            "org_study_id": "HighGradeT1 Bladder Cancer HVH"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HGT1", 
            "high risk bladder cancer", 
            "substaging", 
            "repeat transurethral resection (reTUR)", 
            "lamina propria"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08035"
                }, 
                "name": "Hospital Vall d'Hebron, Barcelona, Spain"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Optimized Treatment Strategy for HighGradeT1 (HGT1) Bladder Cancer Based on Substaging (Depth of Lamina Propria Invasion): a Prospective Observational Cohort Study", 
        "other_outcome": {
            "measure": "Cancer specific survival", 
            "safety_issue": "No", 
            "time_frame": "5year"
        }, 
        "overall_official": {
            "affiliation": "Hospital Vall d'Hebron, Barcelona, Spain", 
            "last_name": "Anna Orsola, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
                "Spain: Departament de Salut de la Generalitat de Catalunya", 
                "Spain: GCP (GCMP/ICH/135/95)", 
                "Spain: Royal Decree 223/2004"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "progression", 
            "safety_issue": "No", 
            "time_frame": "5year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02113501"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "19558557", 
            "citation": "Orsola A, Cecchini L, Ravent\u00f3s CX, Trilla E, Planas J, Landolfi S, de Torres I, Morote J. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Gu\u00e9rin therapy and the decision for a repeat TUR. BJU Int. 2010 Jan;105(2):202-7. doi: 10.1111/j.1464-410X.2009.08694.x. Epub 2009 Jun 24."
        }, 
        "secondary_outcome": {
            "measure": "recurrence", 
            "safety_issue": "No", 
            "time_frame": "5year"
        }, 
        "source": "Hospital Universitari Vall d'Hebron Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitari Vall d'Hebron Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2005", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}